Hansoh says HS-10374 met co-primary endpoints in Phase III
Hansoh Pharmaceutical Group said its HS-10374 met the co-primary endpoints in its Phase III trial for plaque psoriasis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.